<DOC>
	<DOCNO>NCT00126893</DOCNO>
	<brief_summary>This single center Phase 1 study evaluate safety , pharmacokinetics pharmacodynamics CC-401 subject refractory acute myelogenous leukemia .</brief_summary>
	<brief_title>Study Determine Optimal Biologic Dose CC-401 Subjects With High-Risk Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form . Must great equal 18 year age time sign informed consent form . Must diagnosis highrisk myeloid leukemia , define : 1 . Subjects &gt; 70 year age newly diagnose acute myelogenous leukemia ( AML ) ( regardless karyotype ) decline conventional induction chemotherapy ; 2 . Subjects &gt; 60 year age newly diagnose AML poorrisk cytogenetics history secondary AML decline conventional induction chemotherapy ; 3 . Subjects newly diagnose AML experience CR least 2 cycle induction chemotherapy ; 4 . Subjects AML experience second great complete remission 1 2 cycle reinduction chemotherapy ; 5 . Subjects recurrence AML remission duration less three month subject &lt; 60 year age remission duration less six month subject &gt; 60 year age ; 6 . Subjects imatinibrefractory chronic myeloid leukemia ( CML ) blast crisis define &gt; 30 % blast promyelocytes peripheral blood bone marrow smear despite treatment imatinib &gt; 600 mg/daily ECOG performance status &lt; 2 ( see Appendix 2 ) . Serum creatinine &lt; 2 mg/d ALT ( SGPT ) , alkaline phosphatase , conjugate bilirubin &lt; 2 time upper limit normal . No conventional investigational antileukemic treatment within two week administration study drug exception hydroxyurea control peripheral blood blast count . Subjects must recover prior treatmentrelated toxicity . Subject must able adhere study visit schedule protocol requirement . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 7 day start study drug . In addition , sexually active WCBP must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) study drug . WCBP must agree pregnancy test every 4 week study drug . Males ( include vasectomy ) must use barrier contraception ( latex condom ) engage reproductive sexual activity WCBP study medication 4 week last dose study medication Subjects central nervous system ( CNS ) involvement document spinal fluid cytology imaging ; individual sign symptom leukemic meningitis history leukemic meningitis must negative lumbar puncture within 2 week prior enrollment study . Subjects pregnant lactating ; woman childbearing potential must negative urine serum pregnancy test within 14 day prior initial treatment CC401 . Subjects severe life threaten active , unresolved systemic infection . Prior history malignancy myeloid leukemia ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease â‰¥ 3 year . Known HIV1 positivity . Known hepatitis B surface antigen ( HBsAg ) positivity . Prior treatment CC401 Use experimental drug treatment within 28 day baseline Inability provide bone marrow aspirate Subjects severe lifethreatening active bleed refractory platelet transfusion Subjects severe lifethreatening anemia refractory red blood cell transfusion Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>CC401</keyword>
	<keyword>CC-401</keyword>
	<keyword>Celgene</keyword>
	<keyword>High Risk Myeloid Leukemia</keyword>
	<keyword>Myeloid Leukemia</keyword>
</DOC>